Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data
Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data PR Newswire HOUSTON

Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population ...
예상 EPS $5.96 · 매출 $214.12M · 3 명의 애널리스트
예상 EPS $6.47 · 매출 $228.30M · 3 명의 애널리스트
예상 EPS $28.30 · 매출 $869.68M · 3 명의 애널리스트
예상 EPS $7.46 · 매출 $236.65M · 1 명의 애널리스트
EPS $2.56 · 매출 $211.79M
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $875.3M | +82.4% | -2.6% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $70.8M | +35.7% | +40.7% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +50.8% | +24.1% | +58.2% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | +31.5% | +15.7% | +53.9% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | +8.1% | -25.6% | +44.5% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $245.6M | +1077.9% | -57.4% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | +28.1% | +545.9% | -56.2% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 106.7% | -54.1% | -12.6% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 3.41x | +64.3% | +59.0% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $918.5M | +40.2% | +0.8% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | 10.48 vs 14.07 | -25.5% | 9.38 vs 4.95 | +89.3% |
| 매출 서프라이즈 | $875.3M vs $982.4M | -10.9% | $210.8M vs $215.0M | -2.0% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Jaumot Frank E | director | Common Stock | A | 603 | — |
| Jul 31, 2026 | Grenas Cheryl Yvonne | director | Common Stock | A | 603 | — |
| Jul 31, 2026 | Saunders Scott J | director | Common Stock | A | 603 | — |
| Jul 31, 2026 | Reed Michael Lee | director | Common Stock | A | 603 | — |
| Jun 4, 2026 | Spears Kelvin | director | Common Stock | A | 2,519 | — |
Operator: Greetings, and welcome to the Nutex Health's 2026 Second Quarter 10-Q Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Vivian Sanders, Corporate Director of Marketing. Please go ahead. Vivian Sanders: Good morning, everyone, and welcome to Nutex Health, Inc.'s Second Quarter 2026 Earnings Call. My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter. Please note that this call is being recorded for future reference. Joining me this morning are the key leaders driving Nutex Health forward. Our Chairman and CEO, Dr. Tom Vo; our Chief Financial Officer, Jon Bates; our President, Dr. Warren Hosseinion; and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance, strategies and vision, after which we'll open the floor for your questions. Before I turn things over to Dr. Vo, I'd like to take a moment to address a few important points. Today's discussion may include forward-looking statements, which reflect management's current expectations about our future performance. These statements are based on what we know today, but they are subject to risks, uncertainties and other factors that could cause our actual results to differ from what we'll share. For a deeper dive into these forward-looking statements and the factors that may influence them, I encourage you to review the press release and Form 10-Q filed earlier this week as well as our various SEC filings. You'll find all the details there. Additionally, we may reference non-GAAP financial measures such as adjusted EBITDA during the call. For those interested in how these metrics reconcile to GAAP standards, please refer to the press release and Form 10-Q, where that information is included. With those housekeeping items out of the way, it's my pleasure to hand the call over to Dr. Tom Vo, our Founder and Chief Executive Officer. Dr. Tom Vo, the floor is yours. Thomas Vo: Thank you, Vivian, and good morning, everyone. I am happy to join you today to review Nutex Health's second quarter 2026 results. It was an active quarter, marked by strong financial results, important reimbursement developments and continued progress on our growth pipeline, both internally with hospital volume and acuity as well as new pipeline developments. Let me begin with our first 6 months financial and operational performance. For the first 2 quarters of 2026, total revenue reached $427.2 million, a slight 6% decrease from $455.8 million for the same period in 2025. This is primarily due to timing from accrual to cash collections, as Jon will further explain. Net income attributable to Nutex increased to $112.6 million for the first 2 quarters of 2026, a 3,100% increase from $3.5 million for the same …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Thomas T. Vo | Chairman of the Board & Chief Executive Officer | USD 1,527,470 | — | 1973 | Active |
Warren Hosseinion | President & Director | USD 1,199,516 | — | 1972 | Active |
Jon C. Bates | Chief Financial Officer | USD 684,536 | Male | 1971 | Active |
Michael Chang | Chief Medical Officer | USD 549,097 | — | 1972 | Active |
Wesley Bamburg FACHE | Chief Operating Officer | USD 392,722 | Male | — | Active |
Elisa Michael Luqman | Chief Legal Officer of Healthcare & Board Secretary | USD 251,334 | Female | 1964 | Active |
LaTanya Brackens | Director of Compliance | — | Female | — | Active |
Sarah Wallace | Director of Human Resources | — | Female | — | Active |
Jennifer Rodriguez | Investor & Public Relations Manager | — | Female | — | Active |
Vivian Sanders | Director of Marketing | — | Female | — | Active |
Nutex Health Data Breach: Edelson Lechtzin LLP Investigates Theft of Patient and Employee Data PR Newswire HOUSTON

Free case evaluations for individuals affected by the Nutex Health cyberattack claimed by The Gentlemen ransomware group HOUSTON, Sept. 1, 2026 /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a cyberattack on Nutex Health Inc. (NASDAQ: NUTX).

Does Nutex Health Inc. (NUTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

HOUSTON, Aug. 31, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced the awards and honors earned by its hospitals during the second quarter of 2026. Nutex Health hospitals have long served as trusted health care providers in their communities.

NUTX, RCMT, RELY and BDC boast strong net margins, positive earnings estimate revisions and bullish analyst ratings that signal upside.
